Engineering new cellular models to decipher H3.3K27M mutation role in DIPGs' resistance to therapies

被引：0
|
作者：
Rakotomalala, Andria [1 ]
Lewandowski, Paul [1 ]
Bailleul, Quentin [1 ]
Savary, Clara [2 ]
Arcicasa, Melanie [3 ]
Bal, Christine [3 ]
Hamadou, Maud [2 ]
Huchede, Paul [2 ]
Restouin, Audrey [4 ]
Castellano, Remy [4 ]
Collette, Yves [4 ]
Vincent, Audrey [1 ]
Angrand, Pierre-Olivier [1 ]
Adriaenssens, Eric [1 ]
Le Bourhis, Xuefen [1 ]
Leblond, Pierre [5 ]
Castets, Marie [2 ]
Pasquier, Eddy [4 ]
Furlan, Alessandro [1 ]
Meignan, Samuel [3 ]
机构：
[1] Univ Lille, UMR9020, U1277, CANTHER,Canc Heterogenet Plast & Resistance Thera, F-59000 Lille, France
[2] INSERM, U1052, Lyon Canc Res Ctr, F-69008 Lyon, France
[3] Ctr Oscar Lambret, Tumorigenesis & Resistance Treatment Unit, F-59000 Lille, France
[4] Aix Marseille Univ, CNRS, Inst Paoli Calmettes, Ctr Rech Cancerol Marseille,Inserm, F-13009 Marseille, France
[5] Lyon Pediat Hematol & Oncol Inst, F-69008 Lyon, France
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1671
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma
    Bockaj, Irena
    Martini, Tosca E., I
    de Camargo Magalhaes, Eduardo S.
    Bakker, Petra L.
    Meeuwsen-de Boer, Tiny G. J.
    Armandari, Inna
    Meuleman, Saskia L.
    Mondria, Marin T.
    Stok, Colin
    Kok, Yannick P.
    Bakker, Bjorn
    Wardenaar, Rene
    Seiler, Jonas
    Broekhuis, Mathilde J. C.
    van den Bos, Hilda
    Spierings, Diana C. J.
    Ringnalda, Femke C. A.
    Clevers, Hans
    Schueller, Ulrich
    van Vugt, Marcel A. T. M.
    Foijer, Floris
    Bruggeman, Sophia W. M.
    PLOS GENETICS, 2021, 17 (11):
  • [32] Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+patients with diffuse midline glioma' by Immisch et al
    Chheda, Zinal S.
    Mueller, Sabine
    Hegde, Bindu
    Yamamichi, Akane
    Butterfield, Lisa H.
    Okada, Hideho
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (03)
  • [33] THE ONCOHISTONE H3.3K27M DRIVES DIFFUSE INTRINSIC PONTINE GLIOMA INDEPENDENT OF FUNCTIONAL EZH2
    Dhar, Swati
    Becher, Oren
    NEURO-ONCOLOGY, 2018, 20 : 103 - 104
  • [34] H3.3K27M EXPRESSION COMBINED WITH TRP53 LOSS INDUCES HIGH-GRADE GLIOMA
    不详
    CANCER DISCOVERY, 2017, 7 (12) : 1367 - 1367
  • [35] H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers
    Fang, Dong
    Gan, Haiyun
    Cheng, Liang
    Lee, Jeong-Heon
    Zhou, Hui
    Sarkaria, Jann N.
    Daniels, David J.
    Zhang, Zhiguo
    ELIFE, 2018, 7
  • [36] Biophysical characterization of histone H3.3 K27M point mutation
    Hetey, Szabolcs
    Boros-Olah, Beata
    Kuik-Rozsa, Timea
    Li, Qiuzhen
    Karanyi, Zsolt
    Szabo, Zoltan
    Roszik, Jason
    Szaloki, Nikoletta
    Vamosi, Gyorgy
    Toth, Katalin
    Szekvolgyi, Lorant
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 490 (03) : 868 - 875
  • [37] Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+patients with diffuse midline glioma' by Chheda et al
    Immisch, Lena
    Papafotiou, George
    Popp, Oliver
    Mertins, Philipp
    Blankenstein, Thomas
    Willimsky, Gerald
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (03)
  • [38] PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
    Mueller, Sabine
    Taitt, Jared
    Bonner, Erin
    Lulla, Rishi
    Goldman, Stewart
    Banerjee, Anu
    Chi, Susan
    Whipple, Nicholas S.
    Crawford, John
    Gauvain, Karen
    Nazemi, Kellie
    Watchmaker, Payal
    Nejo, Takahide
    Okada, Kaori
    Butterfield, Lisa H.
    Nazarian, Javad
    Villaneuva-Meyer, Javier
    Molinaro, Annette M.
    Prados, Michael
    Okada, Hideho
    NEURO-ONCOLOGY, 2020, 22 : 366 - 366
  • [39] NOVEL NANOPARTICLE-BASED DELIVERY OF H3.3K27M PEPTIDE TO TUMOR-ASSOCIATED MACROPHAGES ENHANCES THE TUMOR HOMING OF H3.3K27M-TCR TRANSDUCED T-CELLS IN HLA-A2/DR1 TRANSGENIC MICE WITH H3.3K27M+
    Yamamichi, Akane
    Chuntova, Polly
    Kakihara, Bunta
    Chen, Tiffany
    Diebold, David
    Harada, Naozumi
    Akiyoshi, Kazunari
    Shiku, Hiroshi
    Okada, Hideho
    NEURO-ONCOLOGY, 2021, 23 : 93 - 93
  • [40] HUMAN IPSC-DERIVED H3.3K27M NEUROSPHERES: A NOVEL MODEL FOR INVESTIGATING DIPG PATHOGENESIS AND DRUG RESPONSE
    Skinner, Kasey
    Koga, Tomoyuki
    Miki, Shunichiro
    Gruener, Robert F.
    Huang, R. Stephanie
    Furnari, Frank
    Miller, C. Ryan
    NEURO-ONCOLOGY, 2021, 23 : 19 - 19
12345